Sarcopenia: Current treatments and new regenerative therapeutic approaches

Jessica Hiu-tung Loa,b,☆, Kin Pong Ua,b,☆, Tszlam Yia,b, Michael Tim-yun Onga,**, Wayne Yuk-wai Leea,b,*

© 2020 The Author(s). Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Available online 30 April 2020

https://doi.org/10.1016/j.jot.2020.04.002

Keywords:
Clinical trial
Exercise
Inflammation
Mesenchymal stem/stromal cells
Mitochondria
Sarcopenia

Introduction- sarcopenia definition and aetiology

According to the United Nation's World Population Ageing 2015 report, the global number of people aged 60 years or above has increased substantially in recent years and is projected to accelerate in the coming decades, doubling the number in 2015 by the year 2050 to an astonishing 2.1 billion people [1]. Ageing is a multifactorial process that is associated with numerous changes in body composition including bone mass, muscle mass, and adipose tissue composition. Muscle, being the largest organ in the body that makes up 40% of the body mass bone mass, muscle mass, and adipose tissue composition. Muscle, being that is associated with numerous changes in body composition including an astonishing 2.1 billion people [1]. Ageing is a multifactorial process the coming decades, doubling the number in 2015 by the year 2050 to increased substantially in recent years and is projected to accelerate in recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Unlike nutraceutical and pharmaceutical interventions that showed controversial results in sarcopenia alleviation, exercise was found to restore mitochondria homeostasis and dampen inflammatory responses via a complex exchange of myokines and osteokines signalling between muscle and bone. However, as exercise have limited benefit to immobile patients, the use of stem cells and their secretome are being suggested to be novel therapeutics that can be catered to a larger patient population owing to their mitochondria restoration effects and immune modulatory abilities. As such, we reviewed the potential pros and cons associated with various stem cell types/secretome in sarcopenia treatment and the regulatory and production barriers that need to be overcome to translate such novel therapeutic agents into bedside application.

Translational potential: This review summarizes the causes underlying sarcopenia from the perspective of mitochondria dysfunction and age-associated inflammation, and the progress of clinical trials for the treatment of sarcopenia. We also propose therapeutic potential of stem cell therapy and bioactive secretome for sarcopenia.

Sarcopenia is characterized by loss of muscle and reduction in muscle strength that contributes to higher mortality rate and increased incidence of fall and hospitalization in the elderly. Mitochondria dysfunction and age-associated inflammation in muscle are two of the main attributors to sarcopenia progression. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Unlike nutraceutical and pharmaceutical interventions that showed controversial results in sarcopenia alleviation, exercise was found to restore mitochondria homeostasis and dampen inflammatory responses via a complex exchange of myokines and osteokines signalling between muscle and bone. However, as exercise have limited benefit to immobile patients, the use of stem cells and their secretome are being suggested to be novel therapeutics that can be catered to a larger patient population owing to their mitochondria restoration effects and immune modulatory abilities. As such, we reviewed the potential pros and cons associated with various stem cell types/secretome in sarcopenia treatment and the regulatory and production barriers that need to be overcome to translate such novel therapeutic agents into bedside application.

Translational potential: This review summarizes the causes underlying sarcopenia from the perspective of mitochondria dysfunction and age-associated inflammation, and the progress of clinical trials for the treatment of sarcopenia. We also propose therapeutic potential of stem cell therapy and bioactive secretome for sarcopenia.

© 2020 The Author(s). Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Available online 30 April 2020

https://doi.org/10.1016/j.jot.2020.04.002

Keywords:
Clinical trial
Exercise
Inflammation
Mesenchymal stem/stromal cells
Mitochondria
Sarcopenia

Introduction- sarcopenia definition and aetiology

According to the United Nation's World Population Ageing 2015 report, the global number of people aged 60 years or above has increased substantially in recent years and is projected to accelerate in the coming decades, doubling the number in 2015 by the year 2050 to an astonishing 2.1 billion people [1]. Ageing is a multifactorial process that is associated with numerous changes in body composition including bone mass, muscle mass, and adipose tissue composition. Muscle, being the largest organ in the body that makes up 40% of the body mass shows an apparent and progressive reduction in the size and number of muscle fibres (up to 30%) in an age-dependent way from 25 to 80 years of age [2]. This loss in muscle mass and consequently its strength results in sarcopenia, a term that describes a prevalent age-associated decline in muscle mass, strength, and function, first introduced by Irwin Rosenberg [3]. Sarcopenia affects 10% (95% confidence interval [CI]: 8–12%) in men and 10% (95% CI: 8–13%) in women, respectively. Meta-analysis indicated that sarcopenia is associated with higher rate of mortality (pooled odds ratio [OR] of 3.596, 95% CI: 2.96–4.37), muscle functional decline (pooled OR of 3.03, 95% CI: 1.80–5.12), higher rate of falls and higher incidence of hospitalization [4]. Epidemiological studies indicated that muscle ageing is associated with a number of degenerative disorders such as osteoporosis, type II diabetes, and cancer [5,6].
It is known that sarcopenia is a multifactorial condition with varying outcomes and can be observed in both older and younger adults, as is likewise the case for dementia and osteoporosis, sarcopenia can be clinically considered “primary” (or age-related) or “secondary” (when one or more other causes are evident) (Supplementary Table 1). Sarcopenia has been underdiagnosed in the past owing to the lack of consensus on clinical definition. The European Working Group on Sarcopenia in Older People defined specific clinical parameters for sarcopenia based on low muscle mass and low muscle function. Thereafter, International Working Group on Sarcopenia published an US guideline in 2011, and Asian Working Group for Sarcopenia provided guidelines for Asian population in 2014. These guidelines (which have been reviewed extensively elsewhere are not included in this review) with ethnic-based modified parameters set the stage for further intensive investigation on the etiopathogenesis and intervention.

In accordance to the European Working Group on Sarcopenia in Older People, sarcopenia is further subgrouped based on the presence of both low muscle mass, low muscle strength, and low physical performance, which dependent on the results and characteristics, was further defined into conceptual stages as “presarcopenia”, “sarcopenia” and “severe sarcopenia” (Supplementary Table 2). The “presarcopenia” stage is characterized by low muscle mass without significant impact on muscle strength or physical performance. This stage can only be identified by techniques that measure muscle mass accurately and in reference to standard populations. The “sarcopenia” stage is characterized by low muscle mass, plus low muscle strength or low physical performance. “Severe sarcopenia” is the stage identified when all three criteria of the definition are met (low muscle mass, low muscle strength, and low physical performance) [7,8]. Recognizing stages of sarcopenia may help in selecting treatments and setting appropriate recovery goals. Staging may also support design of research studies that focus on a particular sarcopenia type [9].

Though the biological mechanism underlying sarcopenia is not clearly understood [10], there is a growing scientific and public interest to develop effective approaches to counteract the effects of sarcopenia to maintain functional independence or known as “active ageing”. In this review, we summarize the definition and consequences of sarcopenia, reviewed how ageing-associated factors, including mitochondria and energy homeostasis dysfunction [11,12], reactive oxygen species (ROS) accumulation [13,14] and inflammation [15] play important roles in the aetiology of age-related sarcopenia. Secondly, we looked into the pros and cons of the currently available therapeutic options, including exercise, pharmaceutical and nutraceutical interventions, for sarcopenia with focus on how exercise alleviates sarcopenia by targeting the mentioned sarcopenia attributing factors and the therapeutic limitation associated with physical exercise. Finally, we reviewed the potential therapeutic effects, pros and cons of administering stem cell and stem cell secretome as novel therapeutic options for sarcopenia and the associated technical and regulatory barriers that need to be overcome.

**Causes of sarcopenia**

**Mitochondria dysfunction and sarcopenia**

Muscle, being the largest organ in the body, is mainly made up of highly contractile and energy-dependent myocytes. To carry out its contractile function, muscle cells receive neurotransmitters such as acetylcholine and dopamine from motor neurons at the motor plate. It is well established that both the muscle and neurons are high energy consuming cells which are greatly addicted to adenosine triphosphate (ATP) supply for them to function and are hence highly dependent on the proper functioning of mitochondria, the powerhouse and ATP supply organelle of the cell.

As age takes toll, mitochondria dysfunction in the muscle started to occur resulting in an increase in levels of apoptosis [16] and reduced capabilities for muscle regeneration [17] that were commonly observed in sarcopenic patients [18]. In addition to the muscular changes, age-related mitochondrial deregulation also results in motor neuronal cell death [19], that ultimately resulted in innervation impairment [20] and an ~27% reduction in the motor unit pool that possibly accounts for the muscular atrophy [20–22] and loss in muscular contractile force in sarcopenic aged humans and rodents [23].

The mitochondria are double membrane bound organelles that contain their own genetic material, the mitochondria DNA (mtDNA) and produces ATP through the electron transport chain process which consists of a series of oxophos reactions [24,25]. The oxophos reactions in mitochondria produces high levels of ROS which are damaging for mtDNA, creating mutations, and deletion in them [26,27]. Hence, mitochondria fission and fusion are in place to maintain mitochondria homeostasis in the cell [25]. Mitochondria fusion and fission are two different processes with fusion being to process that mitigates stress by mixing contents of partially damaged mitochondria as a form of complementation while the latter being the process necessary to create new mitochondria and contribute to quality control of mitochondria via removal of damaged mitochondria [28].

However, as age progresses, mitochondria homeostasis is no longer maintained due to numerous processes, namely the building up of ROS [29] which can be attributed to the reduction in antioxidant enzyme levels in both muscle and neuron cells [30] (Fig. 1). This accumulation of ROS results in mtDNA deletion or mutation causing mitochondrial dysfunction [31,32]. To further add on to the already dire situation, mitophagy–proteosome–induced mitochondria clearance function also deteriorates with age [17,33,34]. As the number of damaged mitochondria accumulates, not only does the mitochondria not able to produce sufficient ATP to sustain cellular function in muscle and neurons, there will also not be enough normal functional mitochondria to act as complementary partners for mitochondria fusion to take place to restore mitochondria homeostasis. These events ultimately lead to damaged mitochondria membrane potential and leakage of mitochondria content to the cell cytosol that initiates apoptosis in both muscle and neurons, leading to muscular atrophy and muscle denervation in sarcopenia (Fig. 2) [28].

**Inflammation in sarcopenia**

In normal physiological conditions, the immune system plays an important role in protecting the body from pathogens. Inflammation is a response elicited by immune cells such as macrophages, dendritic cells, and Th cells in the event of infection to allow the body to clear off pathogens from the body. However, as the body ages, hormonal changes such as decrement in testosterone, growth hormones, androgens, oestrogen occur, and this tips the balance of the body towards a state of chronic inflammation with increased plasma levels of proinflammatory mediators, such as tumour necrosis factor α (TNF-α), interleukin 6 (IL-6), and C-reactive protein (CRP) (Table 1) [35]. This chronic inflammation status causes an increased number of cells to leave cell cycle, enter the state of cellular senescence, and acquire a senescence-associated secretory phenotype (SASP), further inducing the production of proinflammatory cytokines such as TNF-α, IL-6, and NF-κB [35,36] (Fig. 2).

The upregulation of inflammatory cytokines, particularly in the microenvironment of muscle contributes to the upregulation of apoptosis and senescence of myocytes (Fig. 2). Inflammatory cytokines such as IL-6 and TNF-α mainly function as signalling molecules that recruit inflammatory cells into site of infection while concurrently enhance their antiapoptogenic clearance functions such as phagocytosis. However, in the ageing scenario, IL-6 and TNF-α recruit inflammatory cells to the muscle and this initiates the vicious cycle of inducing cellular senescence,
production of SASP, further inflammatory cells recruitment and as a result aged muscle will be overwhelmed by vast amount of inflammatory cytokine, particularly TNF-α [37,38] (Fig. 2). TNF-α functions by binding to receptors on cell surface, initiating the recruitment of adaptor proteins, eventually resulting in a death-induced caspase cascade. This was confirmed by previous findings by Dirks and Leeuwenburgh in 2002 that indicated an elevation in apoptosis (+50%) (measured by nucleosome fragmentation) was observed in 24 months old rats compared with 6 months old young rats [39]. The same group has also reported the higher susceptibility of aged type II muscle fibres to TNF-α stimulated apoptotic signalling, partially attributing to the greater loss of fast twitch muscle fibre with ageing, a phenotype frequently presented in sarcopenia patients [40].

In addition to the apoptotic effects of inflammatory cytokines on myocytes, inflammatory cytokines also affect the muscle regeneration capabilities [41]. Under normal conditions, satellite cells remain in a quiescent state. Upon muscle damage, satellite cells will regenerate damaged muscle by re-entering into cell cycle [42]. However, as the muscle ages, the pool of Pax7 expressing satellite cells decrease resulting in the inability of satellite cells in aged muscle to drive the expression of myogenic differentiation genes such as Myf5 and MyoD [43,44]. The decrement in Pax7 expressing satellite cells along with altered notch signalling, deprivation of growth differentiation factor 11 (GDF11), Igf-1, and increased inflammation and proinflammatory cytokines in age muscle causes deterioration in satellite cell function(s) [45–47] (Fig. 2). As such, inflammation-mediated myocyte apoptosis and loss of satellite cells’ muscle regenerating capabilities are few of the many sarcopenia mediating factors that are targeted by numerous pharmaceutical companies as potential candidates for therapeutic development in addition to nutritional intervention.

**Therapeutic intervention for sarcopenia**

Based on the current understanding on the possible underlying causes of sarcopenia that includes malnutrition, chronic inflammation and lack of exercises, several clinical trials have been conducted to evaluate the feasibility and potential efficacy of using exercise, especially resistant training, commercial nutraceuticals (amino acid, vitamins supplements or mixed compounds), and drug for muscle mass and strength building. A literature search was performed to have a better understanding on the landscape of sarcopenia related clinical studies over the past ten years. In clinicaltrials.gov, a search with the keywords of “sarcopenia” AND “treatment” and inclusion criteria of “10 years” results in 23 registered trials including those with an “Unknown” and “Recruiting” status (Table 2). A PubMed clinical search with “sarcopenia AND intervention” showed 115 clinical trials (excluding 81 irrelevant reports) published over the past ten years. At the time of writing, a total of 34 relevant clinical trials were selected for reporting (Table 2). It appears that exercise and nutraceuticals administration account for about 76% of main treatment strategy for sarcopenia clinical trials; while drugs administration such as testosterone and metformin and whole body electrical myostimulation (WB-EMS) were less frequently adopted therapeutic
Of note, WB-EMS was the only studied physical stimulation for sarcopenia under the searching criteria. Whole body vibration is emerging as alternative physical intervention attracting researchers’ attention most recently [60].

Based on the findings from the ongoing and/or completed clinical trials for sarcopenia training exercise is demonstrated to be the most effective intervention on sarcopenia alleviation. Of a total of 34 studies
Table 1

| Markers | Study | Main findings |
|---------|-------|---------------|
| TNF-α   | [48]  | Elevated plasma TNF-α in elderly (81 years) vs young adults (19–31 years) |
|         | [49]  | Elevated plasma TNF-α in elderly (≥80 years) (2.5 pg/mL) vs young adults (18–30 years) (1.4 pg/mL) |
|         | [50]  | Elevated plasma TNF-α in elderly (60–75 years) (>9 pg/mL) vs young adults (18–30 years) (<7 pg/mL) |
|         | [51]  | Significant correlation between age and TNF-α |
| TNF-α   | [52]  | TNF-α was related to lower appendicular skeletal muscle mass and body cell mass, suggesting that TNF-α contributes to sarcopenia in ageing |
| IL-6    | [53]  | Higher plasma concentrations of IL-6 and TNF-α are associated with lower muscle mass and lower muscle strength in well-functioning older men and women |
| IL-6    | [54]  | Elevated plasma IL-6 in elderly male (55–75 years) vs young male (26–54 years) |
|         | [55]  | Compared three groups of elderly (≥90 years, 80–89 years, 70–79), found elevation in log IL-6 concentration and median IL-6 level with increment in age |
|         | [56]  | Compared three groups of elderly, > 80 years and 71–72 years of age and found elevation in log IL-6 concentration from 0.73 ± 0.66 pg/mL to 0.96 ± 0.65 pg/mL |
|         | [57]  | Elevated plasma IL-6 concentration in elderly > 75 years (>1.4 pg/mL) vs. young adults (20–39 years) (0.6 pg/mL) |
|         | [58]  | Higher plasma concentrations of IL-6 and TNF-α are associated with lower muscle mass and lower muscle strength in well-functioning older men and women |
| hS-CRP  | [59]  | Higher levels of IL-6 and CRP increase the risk of muscle strength loss |
| IL-6    | [60]  | Plasma (CRP) in elderly > 75 years (>2.6 mg/l) vs. young adults (20–39 years) (1.0 mg/l) |
| IL-6    | [61]  | Plasma (CRP) in elderly > 80 years (>2.4 mg/l) vs. elderly 65–69 years (2.2 mg/l) |
| IL-6    | [62]  | Serum (CRP) in elderly ≥ 50 years (≥1.1 mg/l) vs. younger ≥ 30–59 years (≤ 0.95 mg/l) |
| IL-6    | [63]  | Higher levels of IL-6 and CRP increase the risk of muscle strength loss |

IL-6, interleukin 6; CRP, C-reactive protein; TNF-α, tumour necrosis factor α.

listed, only those involving physical activity interventions showed a significant improvement in muscle strength and performance regardless of whether it is aerobic, anaerobic, or resistance type of exercise. On the other hand, nutraceutical and pharmaceutical interventions were not as effective nor did they show promising synergistic effect when administered concurrently with exercise regime.

Physical exercise and sarcopenia

Physical exercise regardless of it being aerobic or anaerobic, high or low resistance has been well accepted to be an important regime to prevent and treat not only chronic and degenerative diseases but also age-associated diseases such as cardiovascular diseases, cancer, neurodegenerative diseases, psychiatric disorders, chronic pulmonary diseases, diabetes, morbid obesity, and sarcopenia [61,62]. Muscle, being the main player in both locomotion and endocrine secretion, it is not surprising to see changes in secretory profile of muscles such as elevation in cytokines (IL-6, IL-8, IL-10, IL-15, CC-chemokine ligand 2 (CCL2), IL-1 receptor antagonist, VEGF), angiotensin-like 4 (ANGPTL4), brain-derived neurotrophic factor, connective tissue growth factor, cysteine-rich angiogenic protein 61, fractalkine and nicotinamide phosphoribosyl transferase upon exercise or physical training [63–65]. As mentioned, inflammation, nutritional deprivation, and mitochondrial dysfunction are well-known factors contributing to sarcopenia progression. The production of exercise-induced cytokines in muscle tips the inflammatory microenvironment of the aged body towards anti-inflammatory. In the immune system, there are cells which are proinflammatory, such as type I macrophage and T-helper cells [66,67], and anti-inflammatory cells such as type II macrophages and regulatory T (Treg) cells [66,67]. In the aged body, where a proinflammatory microenvironment is present, proinflammatory cells are mainly activated, resulting in the production of TNF-α. In the case of exercised muscle, the role of inflammatory cytokines such as IL-6 and chemotactic proteins such as monocyte chemotactic protein 1, fractalkine/CX3CL1 to recruit immune cells, and facilitate their migration and infiltration into the muscle [68], however, concurrently, the production of IL-10 and the IL-1 receptor antagonist switches the proinflammatory reaction to an anti-inflammatory reaction [69] which is reflected by the decrease in systemic concentrations of several inflammatory cytokines which are associated with low-grade systemic inflammatory state such as obesity and insulin resistance, cardiovascular diseases, atherosclerosis, and neurodegenerative disorders [70,71] (Fig. 4).

Other than the anti-inflammatory effects of exercise, physical training also significantly has improvements in the cardiovascular aspects, such as increased cardiac output and enhanced blood volume. One of the most important angiogenic factor produced by skeletal muscle upon physical training is vascular endothelial growth factor (VEGF) [72]. Yet, there is no evidence suggesting an altered VEGF level after training, indicating that VEGF increment and its effects are mainly localized to the muscles [73] (Fig. 4). In addition to the localized release of VEGF, extracellular matrix associated proteins, cysteine-rich angiogenic protein 61/CNN1 and connective tissue growth factor/CNN2 [74], together with IL-8 are elevated after exercise, and these molecules have been proposed to play important roles in skeletal angiogenesis by activating endothelial cell proliferation, capillary tube organization, and extracellular matrix remodelling. Finally, the production of ANGPTL4 in exercised muscle further enhances the angiogenesis in skeletal muscle, and it also increases vascular permeability and lipid metabolism muscle. These secretory angiogenic factors in all produce an enhanced angiogenic effect in muscle, allowing more blood being supplied to the muscle and more efficient nutrient delivery to the muscle tissue, an important function in preventing and delaying the progress of sarcopenia [75] (Fig. 4).

Finally, it is a well-known fact bone and muscle have a very close working relationship as such secretory factors from muscles are known to regulate bone development or remodelling and vice versa. In vitro study demonstrated that conditioned medium of osteocyte cells could stimulate myogenic differentiation of C2C12 myoblasts. [76] (Fig. 4). Moreover, exercised induced mechanical loading has been shown to induce production of IGF-1, VEGF, and hepatocyte growth factor in osteocytes cell line, which may play roles in regulating muscle growth [77,78]. Importantly, physical training also induces the production of osteocalcin (OCN), an osteoblast-derived hormone which was shown to promote adaptation to exercise in mice [134]. Finally, it was also found that older adults with regular exercise expressed an increased activity of mitochondrial oxidative enzymes and expression of mitochondrial biogenesis genes such as PGC-1, NRF-1, and TFAM, suggesting that physical training is able to enhance and even restore mitochondria function and homeostasis via direct or indirect stimulation of mitochondria biogenesis (Fig. 4) [79].

Limitation of physical exercise in sarcopenia treatment

Despite its effectiveness as a sarcopenia therapeutic regime, exercise intervention is only available to patients or elderly who are reasonably mobile, in other words, exercise intervention is not expected to benefit bedridden patients despite the fact that these are the patients who needed such intervention the most (Table 3). Furthermore, as physical abilities vary from patients to patients, it is essential to customize exercise regime for individual patient to maximize its beneficial effect, making physical training for a huge population of patients unrealistic and difficult. As such other sarcopenia interventions such as whole-body electricity myostimulation and vibration have been proposed as potential emerging therapeutic interventions which are able to cater to the
List of sarcopenia clinical trials using nutraceuticals, protein supplements and exercise as therapeutic interventions individually or concurrently.

| Year | Sample size/ gender | Age (mean or average) | Treatment method | Cotreatment | Treatment | Control groups | Longest follow-up time point | Assessment | Reference |
|------|---------------------|-----------------------|------------------|-------------|-----------|----------------|-----------------------------|------------|----------|
| 2013 | 170/ Women          | ≥65                   | Drug             | Vitamin D and protein supplementation | MK-0773 50 mg twice daily | Placebo | 6-month | DXA, muscle strength power; physical performance measures | [80] |
| 2015 | 380/All             | ≥65                   | Nutritional supplement | Vitamin D and leucine-enriched whey protein nutritional supplement twice daily | Isocaloric control product twice daily | 13-week | Handgrip strength, SPPB score, chair-stand test, gait speed, balance score, appendicular muscle mass (by DXA) | [81] |
| 2016 | 330/All             | ≥65                   | Nutritional supplement | Contained other vitamins, minerals, and nutrients in varying amounts | Experimental ONS (E ONS, 20 g protein; 499 IU vitamin D 3; 1.5 g CalMB) taken twice daily | Control ONS (C ONS, 14 g protein; 147 IU vitamin D 3) | 24-week | Isokinetic peak torque leg strength, grip strength, gait speed (m/s – 1), Left and right leg muscle mass (by DXA), Muscle quality (MQ) was leg strength expressed relative to the tested LMM Sarcopeina Z-Score, body fat rate (%), skeletal muscle mass index, handgrip strength | [82] |
| 2017 | 100/ Men            | ≥70                   | Physiological intervention and Nutritional supplement | WB-EMS and protein supplementation (WB-EMS&P) Isolated protein supplementation | Non-intervention control | 16-week | Body composition (by DXA), muscle quality defined as a ratio of muscular strength to muscle mass, physical capacity assessed using functional mobility tests | [83] |
| 2017 | 46/ Women           | 67.3                 | Exercise | EG underwent elastic RET Each exercise session involved a general warm-up of 10 min, followed by resistance training exercises (35–40 min), and finally a cool-down routine | No RET intervention | 12-week | Fat-free mass, muscle strength, physical performance | [84] |
| 2018 | 110/ All            | Mean age 73.8        | Exercise | Education including home-based exercise | LEE group consisted of different modalities of exercise | 3-month | Body composition (by DXA), maximum strength | [85] |
| 2014 | 76/ Women           | Mean age 75          | Physiological intervention | WB-EMS group (WB-EMS, n = 38) that performed 18 min of WB-EMS (bipolar, 85 Hz) 3 sessions in 14 days (1.5 sessions/week) | Semi-active control group | 54-week | Body composition (by DXA), maximum strength | [86] |
| 2017 | 35/ Women           | ≥60                  | Exercise | Study group underwent progressive elastic band resistance training for 12 weeks (3 times per week) | A 40-min lesson about the exercise concept silica | 12-week | DXA | [87] |
| 2015 | 60/Men              | ≥65                  | Exercise and Nutritional supplement | Collagen peptide supplementation (15 g/d) | Control (CON) group consumed placebo pills (high oleic sunflower oil; 4 g/day) | 6-week | Change in FFM Fat-free mass, Body composition (by DXA), Muscular strength (by measuring isokinetic quadriiceps strength) | [88] |
| 2017 | 46/All              | 61–77 years          | Nutritional supplement | Phytochemical compound Protandim® (LifeVantage) at the commercially available dose (one pill/day) Conjugated linoleic acid (CLA; 4 g/day) | Control (CON) group consumed placebo pills (high oleic sunflower oil; 4 g/day) | 6-week | Body composition (by DXA) | [89] |
| 2015 | 60/All              | 60–85 years          | Nutritional supplement | n-3 PUFA consume 2 pills in the morning with breakfast and 2 pills in the evening with dinner | Placebo control (4 identical looking pills/d that | 6-month | Thigh muscle volume, handgrip strength, one-repetition maximum (1-RM) | [90] |

(continued on next page)
| Year | Sample size/ gender | Age (mean or average) | Treatment method | Cotreatment | Treatment | Control groups | Longest follow-up time point | Assessment | Reference |
|------|---------------------|-----------------------|-------------------|-------------|-----------|----------------|---------------------------|------------|-----------|
| 2016 | 30/ Women           | Aged 61-86 years      | Exercise          | Practice sessions for the maximum voluntary isometric contraction (MVIC) and knee extension and leg press 1RM test | Two training groups performed bilateral squat and knee extension exercise training 2 days/week for 12 weeks | The MH-Tr group exercised at two exercise intensities ranging from 5.6 to 8.4 on the OMNI perceived exertion scale for resistance exercise (OMNI-RES) for active muscle scale (0=extremely easy to 10=extremely hard) which has been noted to correspond to exercise intensity levels ranging from approximately 70%-90% of 1RM for women. The BFR-Tr group used one gold band for squatting, and one black (Special Heavy) band for knee extension. The gold band was approximately twice the resistance level as the black band, thus the two exercises for the BFR-Tr group were one-half (low-intensity level) the intensity as that for the MH-Tr group. | no training (Ctrl, n = 10) groups | 12-week | MRI-measured muscle cross-sectional area (CSA) at mid-thigh, maximum voluntary isometric contraction (MVIC) of knee extension, central systolic blood pressure (c-SBP), central-augmentation index (c-Aix), cardiac-ankle vascular index testing (CAVI), ankle-brachial pressure index (ABI). | [91] |
| 2018 | 99/Men              | Aged ≥65              | Drug              | Receive 10 g of a transdermal gel (100 mg of testosterone) | Placebo | 6-month | mTcChe strength and physical function (assessed by loaded stair-climbing power) | Handgrip strength, gait speed, myostatin serum level, and health-related quality of life (HR-QoL) | [92] |
| 2017 | 91/All              | Aged ≥60              | Drug              | 3 × 500 mg metformin (every 4 weeks) | Placebo group | 16-week | Body composition (by DXA), muscle strength (1-repetition maximum leg press and chest press) | [93] |
| 2015 | 64/All              | Aged 50-71 years      | Nutritional supplement | Creatine before (CR-B: n = 15; creatine (0.1 g/kg) immediately before resistance training and placebo (0.1 g/kg cornstarch maltodextrin) immediately after resistance training), creatine after (CR-A: n = 12; placebo immediately before resistance training and creatine immediately after resistance training) | Placebo (PLA: n = 12; placebo immediately before and immediately after resistance training) | 32-week | Body composition (by DXA), muscle strength (1-repetition maximum leg press and chest press) | [94] |
| 2015 | 79/All              | Mean age 73.8         | Nutritional supplement | Patients received calcium 1 g and vitamin D 800 IU; specifically, cholecalciferol (Calcichew-D3®; Takeda Pharmaceutical Company Limited, Osaka, Japan) | Controls (group C, n = 25) received calcium 1 g and vitamin D3 800 IU daily | 12-month | Body composition (by DXA), handgrip strength (HGS) and health-related quality of life | [95] |

(continued on next page)
| Year | Sample size/ gender | Age (mean or average) | Treatment method | Cotreatment | Treatment | Control groups | Longest follow-up time point | Assessment | Reference |
|------|---------------------|-----------------------|------------------|-------------|-----------|----------------|---------------------------|------------|-----------|
| 2017 | 50/All | Mean age 70.6 | Nutritional supplement | Participated in lower-limb resistance exercise training twice weekly | Long-chain n-3 PUFAs (n = 23; 3 g fish oil/d) | Placebo (n = 27; 3 g safflower oil/d) | 18-week | Muscle size, strength, and quality (strength per unit muscle area), functional abilities, and circulating metabolic and inflammatory markers | [96] |
| 2016 | 15/Men | Aged 62-66 | Drug | Progressive resistance exercise training program of bilateral knee extension that was designed to hypertrophy and strengthen the m. quadriceps femoris | COX inhibitor (acetaminophen, 4 g/day; n = 7; 64 ± 1 years) | Placebo (n = 8; 64 ± 2 years) | 12-week | Muscle samples were examined for Type I and II fiber cross-sectional area, capillarization, and metabolic enzyme activities (glycogen phosphorylase, citrate synthase, β-hydroxyacyl-CoA-dehydrogenase) | [97] |
| 2018 | 54/All | Mean age 82.4 | Exercise and Nutritional supplement | Elastic band resistance training (N. = 16) nutritional supplementation (N. = 21) | Control group (N. = 17) | 6-month | Skeletal muscle mass (by DXA), isokinetic knee extension and flexion force and handgrip strength | [98] |
| 2016 | 20/Men | Aged 55-75 years | Exercise | Ingest 30 g protein from a soy-dairy PB (n = 9) or WPI beverage (n = 10) at 1 h post-RE | | 1 day | Blood and muscle amino acid concentrations and basal and postexercise muscle protein turnover | [99] |
| 2014 | 100/All | Aged ≥60 | Nutritional supplement | 210 g of ricotta cheese (IG/HD + RCH) | Control group was instructed to consume only their habitual diet (CG/HD) | 12-week | Appendicular skeletal muscle mass (by DXA), handgrip strength by a handheld dynamometer, and physical performance using the short physical performance battery (SPPB) and the stair-climb power test (SCTP) | [100] |
| 2013 | 54/All | Aged ≥65 | Nutritional supplement | Phase I consisted of two non-exercise groups: (a) placebo and (b) 3 g CaHMB consumed twice daily. Phase II consisted of two resistance exercise groups: (a) placebo and resistance exercise and (b) 5 g CaHMB consumed twice daily and resistance exercise (RE) | | 24-week | Strength and functionality were assessed in both phases with isokinetic leg extension and flexion at 60°·s⁻¹ and 180°·s⁻¹ (LE60, LF60, LI610, LF180), hand grip strength (HG) and get-up-and-go (GUG). DXA was used to measure arm, leg, and total body lean mass (LM) as well as total fat mass (FM). Muscle Quality was measured for arm (MQ(HG) = HG/arm LM) and Leg (MQ60 = LE60/leg LM) (MQ180 = LE180/leg LM), DXA, maximal voluntary isometric contraction, maximal 900 m effort | [101] |
| 2017 | 57/ Women | Aged 50-70 years | Exercise and Nutritional supplement | Consumed 0.33 g/kg body mass of a milk-based protein matrix (PRO) | Engaged in a PRT intervention (PRO + PRT) | Consumed 0.33 g/kg body mass of a milk-based protein matrix (PRO) | 12-week | DXA, maximal voluntary isometric contraction, maximal 900 m effort | [102] |
| 2013 | 46/ Women | Mean age 75 | Physiological intervention | WB-EMS group (n = 23) which performed 18 min of intermittent, bipolar WB- | “Active” control group (n = 23) | | Whole-body and regional body composition was assessed by (DXA) to | [103] |
| Year | Sample size/gender | Age (mean or average) | Treatment method | Cotreatment | Treatment | Control groups | Longest follow-up time point | Assessment | Reference |
|------|---------------------|-----------------------|------------------|-------------|-----------|----------------|----------------------------|------------|-----------|
| 2015 | 52/All Mean age 78  | Exercise              | EMS (85 Hz) three sessions in 14 days | determine appendicular muscle mass, upper leg muscle mass, abdominal fat mass, and upper leg fat mass. Maximum strength of the leg extensors was determined isometrically by force plates. Neuromuscular activation was assessed using surface electromyography and muscle cross-sectional area (CSA) was measured using computed tomography. | 16-week | [104] |
| 2013 | 80/All Aged 70-85   | Nutritional supplement | Completed a progressive high-intensity RT intervention | Change in whole-body lean Muscle cross-sectional area, muscle strength increased, Stair-climbing performance Circulating levels of myostatin, activin A, follistatin, IGF-1 and GDF-15, as well as MQ and functional parameters | 6-month | [105] |
| 2016 | 91/Women Mean age 83.6 | Exercise | Intervention groups (RT, resistance training; RTS, resistance training plus nutritional supplementation; CT, cognitive training) | Muscle biopsies slow and fast fibres included fibre diameter, peak force (P0), rate of tension development, maximal shortening velocity, peak power, and Ca(2+) sensitivity. | 6-month | [106] |
| 2015 | 19/All Aged 61-71   | Drug                  | Continuous T (WK, n = 5; 100 mg T enanthate, im injection) monthly cycled T (MO, n = 7; alternating months of T and placebo) | Muscle Power | 5-month | [107] |
| 2009 | 81/All Aged 65-85   | Exercise              | A 10-week unilateral ST program using the untrained leg as an internal control preceded 12 weeks of whole-body ST | Body composition Mid-Thigh Subcutaneous Fat, Intermuscular Fat, and Muscle Volume of the Knee Extensors Muscle strength Muscle power Muscle Power | 22-week | [108] |
needs of larger group of patients. However, more trials with larger patient population will be needed to effectively determine their efficacy.

New therapeutic approaches – the pros and cons of stem cell transplantation and potential alternatives in sarcopenia

Despite potential novel interventions are being developed in a timely manner, the number of effective options available against sarcopenia till date is still restricted solely to exercise as pharmaceutical intervention options for sarcopenia is limited and ineffective as it is a multifactorial age-associated condition (Fig. 1) (Table 3). Hence, novel therapeutic interventions that are able to concurrently promote mitochondria biogenesis or restore mitochondrial functions, reduce age-associated inflammation response in muscle tissue, and promote muscle tissue regeneration and thereby restoring muscle strength must be developed to elicit an effective treatment or synergistic effect when used alone or concurrently with exercise.

Regenerative medicine and stem cell therapy are attractive therapeutic intervention strategies for age-associated conditions such as neurodegenerative diseases and cardiovascular diseases, and so on owing to their ability to regenerate and repair damaged parts of the body. Stem cells are defined as cells with infinite replication capabilities and the ability to differentiate into mature somatic cells such as neurons and muscle [109]. Therefore, in view of the aetiology of sarcopenia, stem cell transplant could be a potential therapeutic strategy. However, that brings out numerous therapeutic associated questions such as the type of stem cells to be use, the safety and efficiency of stem cells, and most importantly in the pharmaceutical manufacturing process, how are the stem cells defined and what are the quality control in placed to ensure product consistency and stability?
Figure 4. A schematic illustration of alleviating sarcopenia via exercise. Exercise stimulates muscular contraction which in turn stimulate myocytes to produce myokines that can enhance muscle innervation, stimulate angiogenesis in muscle, and stimulate satellite cell proliferation and differentiation. Exercise also stimulates the bones directly via mechanical loading or indirectly via muscular contraction. Stimulation of the bones by exercise activates osteocytes to produce osteokines that can promote satellite cells proliferation and differentiation, promote muscle growth and induce mitochondria biogenesis. The overall effects of myokines and osteokines switch the microenvironment towards an anti-inflammatory spectrum that supports angiogenesis, neurogenesis, and myogenesis.

Table 3
Pros and cons of sarcopenia therapeutic strategies.

| Current strategies | Treatment | Pros | Cons | Reference |
|--------------------|-----------|------|------|-----------|
| Nutritional        | Protein supplements | Improve the muscle mass | Not improve the muscle strength and physical performance | [110] |
| supplementation     | Essential amino acid (EAA) supplementation | Improve the muscle mass | Not improve the muscle strength and physical performance in elder women | [111] |
|                    | β-hydroxy β-methylbutyric acid (HMB) supplementation | Not consistent in several studies regarding muscle mass, strength and physical performance. | | [101], [112], [113] |
|                    | Fatty acid supplementation | Improved both muscle volume and physical performance | Need further investigation on the dosage and frequency use | [90], [114] |
| Exercise            | Resistance training | Increased muscle mass and strength, skeletal muscle protein synthesis and muscle fibre size and improvement in physical performance | Motivation to exercise in older adults is low Highly dependent on patients' mobility | [7] |
| Medications         | Aerobic exercise | Increase mitochondrial volume and activity | | [7] |
|                    | ACE inhibitors | Some evidence for increased exercise capacity | Renal function needs monitoring | [7] |
|                    | Myostatin inhibitors | Enhance muscle lean mass | No conclusive idea on muscular strength and physical performance improvement. | [115] |
|                    | Testosterone | May increase muscle strength and physical performance and decrease fat mass and hospitalization in older adults. | Side effect, such as CVDs, fluid retention, gynaecomastia, worsening of sleep apnoea, polycythaemia, and acceleration of benign or malignant prostatic disease can be observed | [116] |
|                    | Growth hormone | Increased lean tissue mass and decreased fat mass | Side effects may be induced fluid retention, orthostatic hypotension, cancer induction. | [116, 117] |
Embryonic stem cells and induced pluripotent stem cells

Up till now, there are three main types of stem cells, namely embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and adult stem cells. ESCs and iPSCs are defined as pluripotent stem cells with the potential to give rise to tissues from three primary germ layers. However, unlike ESCs which are mainly derived from the inner cell mass of the blastocyst, which is a stage of preimplantation embryo that usually occurs 5–6 days after fertilization, iPSCs are man-made pluripotent stem cells that are produced by introducing pluripotency genes, such as Sox2, Klf4, Oct3/4 and c-myc, which are collectively known as Yamanaka factors, into somatic cells and reprogramming them back to a pluripotent state [109,118,119]. However, since the beginning of the use of ESCs/iPSCs in research, not only are many ethical restrictions are being formed in place that limit the application of ESCs/iPSCs in therapeutic interventions for human, the safety concern over the formation of teratoma by ESCs/iPSCs in transplanted patient is also a major concern that limits the medical application of ESCs/iPSCs.

Somatic or adult stem cells

Somatic or adult stem cells on the other hand, are undifferentiated and found among differentiated cells in the whole body after development. Their main function is to enable healing, growth and replacement of cells that are lost everyday [120]. The more well-known examples of adult stem cells include mesenchymal stem/stromal cells (MSCs), neural stem cells, haematopoietic stem cells, and satellite cells [109,120–122]. As sarcopenia is a muscular degenerative disease in which loss of Pax7 satellite cells was known to attribute to sarcopenia progression, it is therefore sensible to derive and expand Pax7 satellite cells followed by transplantation of sufficiently expanded satellite cells into sarcopenic muscle [122,123]. However, such transplantation strategy did not take into account of the proinflammatory environment in aged muscle, which is detrimental for the transplanted satellite cells. Furthermore, the population of Pax7 satellite cells present in the muscle is too little, making isolation and expansion in vitro a huge challenge [122,123]. More importantly, in the aspect of pharmaceutical manufacturing, the European Medicines Agency have set Good Manufacturing Practice guidelines for Advanced Therapy and Medicinal Products, which stated the importance of having proper quality control measures to stability in medicinal products, in this case Pax7 satellite cells. However, it has been reported by multiple research groups that satellite cell culture is extremely unstable under in vitro culture condition with Pax7 expression and Pax7 positive cells dropping with every cell passage [124]. Hence, to effectively apply satellite cells in sarcopenia treatment, it is paramount to resolve the issue on how to effectively derive and expand satellite cells without losing their Pax7 positivity.

Mesenchymal stem/stromal cells

MSCs on the other hand are attractive stem cells to be used in therapeutics development owing to their high abundance and presence in many tissues such as fat, bone marrow, dental pulp, and umbilical cord [120,125,126]. Moreover, MSCs are easily scalable in vitro and hence MSCs are used in many clinical trials targeting a huge range of diseases and conditions from neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, autoimmune disease such as multiple sclerosis to injury conditions such as spinal cord injury and stroke [127–131]. Interestingly, many MSC transplantation/therapeutic effects were found to be mainly owing to their immune modulating effects that include the production of anti-inflammatory cytokines such as IL-10 and IL-13 [127,128,130]. In addition, MSCs have also been reported to secrete basic fibroblast growth factor, VEGF, monocyte chemotactic protein 1 which are also known to have a neuro-supportive effect [132,133]. This creates an anti-inflammatory microenvironment which is beneficial for endogenous stem cells in the damaged tissue to carry out essential repair and thereby restoring tissue function. Given the proinflammatory microenvironment and innervation condition in aged muscle which attributes to sarcopenia progression, transplantation of MSCs might be able to tip the proinflammatory microenvironment in aged muscle to an anti-inflammatory microenvironment which is beneficial for the endogenous satellite cells to carry out muscle regeneration while at the same time stimulating muscular innervation by the peripheral nervous system. It was also suggested that MSC could mediate mitochondria transplantation into aged cells which could have a therapeutic benefit by restoring mitochondrial function in both the muscle cells and neuronal cells in aged muscle. However, the efficiency and effects of mitochondria transplant by MSCs remain to be debated. Most importantly, as protocol for MSCs manufacturing is more established it is easier from the manufacturing point of view to set up in-process quality control parameters to minimize batch to batch variation in MSCs, potentially making them the more suitable candidate for cellular transplantation in sarcopenia.

Yet, cellular transplantation, such as organ transplantation, involves the administration of cells which could come from a foreign source, in other words, to allow the transplantation to work, patients might need to undergo vigorous regime of steroids to improve the survival of cellular transplant in their body, that can be detrimental to the body. Hence, to overcome the restrictive hurdles yield by stem cell transplantation and by support of the fact that the therapeutic effects mediated by transplanted stem cells could be elicited by secreting factors produced by the stem cells, it is therefore sensible to administer secretory factors instead of cells into target tissue to enable tissue repair and regeneration. Through the approach of administering secretome of stem cells, manufacturing hurdles involving quality controls that minimize batch to batch variation can be easily put in place owing to higher product stability. Furthermore, the manufacturing cost can be lowered as harvesting of stem cell secretome can be carried out via continuous culture medium harvesting manner, similar to a fed-batch fermentation rather than a batch manufacturing that involves resuscitation of a new batch of stem cells.

Conclusion

In conclusion, sarcopenia is an age-associated loss of muscle mass that involves numerous attributing factors. Stem cell therapy could potentially be a novel therapeutic intervention for sarcopenia alleviation owing to its regenerative capabilities and its ability to produce anti-inflammatory cytokines that in turn change the microenvironment into one that promotes reinnervation and regeneration. However, stem cell transplantation is limited by several factors, ranging from ethics, rejection and production limitations and hence, using the secretome of stem cells, which is the main anti-inflammatory component produced by stem cells could be a better option over the direct use of stem cells. More importantly, until now, numerous studies for sarcopenia has looked into the effects of exercise, nutraceutical and protein supplements in sarcopenia alleviation but none has looked at the effects of exercise along with the concurrent use of stem cell secretome, which could be a novel anti-sarcopenia approach that could potentially provide an even better outcome than the other classical approach.

Conflicts of interest statement

The authors have no conflicts of interest to disclose in relation to this article.

Acknowledgement

This work was supported by CUHK MARS Scanner Project, Hong Kong (7106251) and Health and Medical Research Fund, Hong Kong (06170546).
Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi. org/10.1016/j.jot.2020.04.002.

References

[1] Beard JR, Officer AM, Canesh AE. The World report on ageing and health. Gerontol 2016;56(Suppl 2):S163–6.
[2] Leslex J, Taylor CC, Sjostrom M. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 5- to 83-year-old men. J Neurol Sci 1996;148(2):169–75.
[3] Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr 1997;127(Suppl). 9905-8.
[4] Beaudart C, Zaria G, Patteau F, Register JY, Bruyere O. Health outcomes of sarcopenia: a systematic review and meta-analysis. Flso One 2017;12(1), e0169548.
[5] Ayya D, Dennison EM, Sydall HE, Gilbody HJ, Phillips DI, Cooper C. Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg? Diabetes Care 2005;28(10):2541–2.
[6] Prado CM, Cauwen SJ, Oruso CE, Ryan AM. Sarcopenia and cachexia is the era of obesity: clinical and nutritional impact. Proc Nutr Soc 2016;75(2):188–98.
[7] Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an updated condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working on sarcopenia. J Am Med Dir Assoc 2012;13(4):249–56.
[8] Cruz-Jentoft AJ, Bauer J, bou R, Bohn AL, Schols JM, et al. Sarcopenia: revised European consensus on definition and diagnosis. Ageing Ageing 2019;48(1):23–32.
[9] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing 2010;39(4):412–23.
[10] Burton LA, Sumukadas D. Optimal management of sarcopenia. Clin Interv Aging 2010;5:217–26.
[11] Sakellarious GR, Vanlakili A, Palomero J, Kayani A, Zibrlik I, McArdle A, et al. Studies of mitochondrial and nonmitochondrial sources implicate nicotinamide adenine dinucleotide phosphate oxidase(s) in the increased skeletal muscle superoxide generation that occurs during contractile activity. Antioxidants Redox Signal 2015;18(6):603–21.
[12] Short KR, Bigelow ML, Kahl J, Singh R, Coenen-Schimke J, Raghavakaimal S, et al. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A 2005;102(13):4568–23.
[13] Palomero J, Vanlakili A, Pye D, McArdle A, Jackson MJ. Aging increases the oxidation of dichlorohydrofluorescein in single isolated skeletal muscle fibers at rest, but not during contractions. Am J Physiol Regul Integr Comp Physiol 2013;305(4):R251–4.
[14] Broome CS, Kayani AC, Palomero J, Dillmann WH, Mestril R, Jackson MJ, et al. Effect of lifelong overexpression of HSP70 in skeletal muscle on age-related oxidative stress and adaptation after noncontrad muscle activity. Faseb J 2006;20(9):1599–9.
[15] Lopez-Otin C, Blanco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153(6):1223–41.
[16] Marzetti E, Leeuwenburgh C. Skeletal muscle apoptosis, sarcopenia and frailty at old age. Exp Gerontol 2011;46(12):1234–43.
[17] Garcia-Prat L, Sousa-Victor P, Munoz-Canoves P. Functional dysregulation of stem cells during aging: a focus on skeletal muscle stem cells. FEBS J 2013;280(17):956–7.
[18] Keramati A, Rezvani A, Soroush M, Vahid M, Soroush M. Sarcopenia: an undiagnosed condition in older adults. J Am Med Dir Assoc 2011;12(4):249–52.
[19] Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger Jr WH, et al. The origins of age-related proinflammatory factors IL-6 and TNF-alpha. J Am Med Dir Assoc 2004;5(5):196–203.
[20] Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an updated condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working on sarcopenia. J Am Med Dir Assoc 2012;13(4):249–56.
[21] Hurvitz A, Wagers AJ. Skeletal muscle stem cells: effects of aging and metabolism on muscle regeneration factor. Cold Spring Harbor Symp Quant Biol 2008;73:323–31.
[22] Collins CA, Zammit PS, Ruiz A, Morgan JE, Partridge TA. A population of myogenic stem cells that survives skeletal muscle aging. Stem Cell 2007;25(4):885–94.
[23] Jing YC, Sinha M, Cerletti M, Dall’Ossio C, Wagers AJ. Skeletal muscle stem cells: effects of aging and metabolism on muscle regeneration factor. Cold Spring Harbor Sym Quant Biol 2011;76:101–11.
[24] Harridge SD. Ageing and local growth factors in muscle. Scand J Med Sci Sports 2003;13(3):34–9.
[25] Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005;433(7027):760–4.
[26] Bruaunghard H, Skirvin WN, Peterson AN, Schurr M, Pedersen BK. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol 2000;121(2):255–60.
[27] Bruaunghard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skirvin WN. The plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 1999;54(7):M357–64.
[28] Paolisso G, Rizzo MR, Mazzotti G, Tagliamonti MR, Gambardella A, Rotondi M, et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol 1998;275(2):E294–9.
[29] Pedersen BK, Storlien LH, Furey AS, Pedersen JE, Hovde P, Guay B, et al. Plasma concentrations of tumor necrosis factor-alpha in relation to body mass index and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 2003;124(4-5):495–502.
[30] Vissing M, Pahor M, Taaffe DR, Goodpaster BH, Simonick EM, Newman AB, et al. Relationship of interleukin-6 and tumour necrosis factor-alpha interferon with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 2002;57(9):M326–32.
[31] Wei J, Xu H, Davies J, Hemmings GP, Irelan GS. Distribution of plasma IL-6 concentration in healthy subjects. Life Sci 1992;51(25):1953–6.
[32] Cohen HJ, Peiper CF, Harris T, Rao KM, Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci 1997;52(4):M201–8.
[33] Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger JR, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in older adults. J Am Med Dir Assoc 2006;7(6):506–12.
[34] Ferrucci L, Corsi A, Landefini F, Blandini S, Bartali B, Taub DD, et al. The origins of age-related proinflammatory state. Blood 2005;106(5):2294–9.
Olfert IM, Baum O, Hellsten Y, Egginton S. Advances and challenges in skeletal muscle angiogenesis. Am J Physiol Heart Circ Physiol 2016;310(3):H326–49.

Nieman DC, Henson DA, Smith LL, Utter AC, Vinci DM, Davis JM, et al. Cytokine and treatment of disease. Nat Rev Immunol 2011;11(9):607–18.

Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.

Papanicolaou DA, Ather SN, Zhu H, Zhou Y, Lutkiewicz J, Scott BB, et al. A phase II randomized, double-blind, placebo-controlled clinical study to test the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. J Nutr Health Aging 2013;17(6):533–43.

Bauer JM, Verlaan S, Baumann I, Brandt K, Donini LM, Maggio M, et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROSPECT study: a randomized, double-blind, placebo-controlled clinical trial. J Am Med Dir Assoc 2015;16(9):740–5.

Cramer JT, Cruz-Jentoft AJ, Landi F, Hickson M, Zamboni M, Pereira SL, et al. A single bout of exercise with high mechanical loading induces the expression of Cyr61/c-Myc in non-diabetic pre-frail elderly patients. Acta Med Indones 2017;49(2):118–27.

Candow DG, Vogt E, Buehler DW, Forbes SC, Farthing JP. Strength training and resistance supplementation and resistance training in healthy older adults. Appl Physiol Nutr Metab 2015;40(7):589–94.

Flodin I, Cederholm T, Saaf M, Samnegard E, Ekstrom W, Al-Ani AN, et al. Effects of green-flavonoid-rich nutritional supplements on body composition, handgrip strength and health-related quality of life after hip fracture: a 12-month randomized controlled study. BMC Geriatr 2015;15:149.

Boit M, Sibon R, Sivanubramaniam S, Meakin JR, Greig CA, Aspden RM, et al. Sex differences in the effect of fish oil supplementation on the adaptive responses to resistance exercise training in older people: a randomized controlled trial. J Am Clin Nutr 2017;105(1):151–4.

Trapej TA, Fatchford SM, Brower BE, Liu SZ, Lavin KM, Carroll CC, et al. COX inhibitor reduces muscle fiber size and strength adaptations to resistance exercise in older adults. J Gerontol A Biol Sci Med Sci 2016;71(10):1289–99.

Strasser EM, Hofmann M, Franzke B, Schober-Halper B, Oesen S, Jandrasits W, et al. Strength training increases skeletal muscle quality but not muscle mass in old institutionalized adults: a randomized, multi-arm parallel and controlled intervention study. Eur J Phys Relabil 2018;54(4):921–33.

Alleman-Mateo H, Castano J, Andretta D, Aguilar AC, Enriquez JR. Nutrient-rich dairy proteins improve appendicular skeletal muscle mass and physical performance, and attenuate the loss of muscle strength in older men and women subjects: a single-blind randomized clinical trial. J Intern Med Aging 2016;4(2):207–25.

Stout JR, Smith-Ryan AE, Fukuda DH, Kendall KL, Moon JR, Hoffman JR, et al. Protein supplementation and resistance training in healthy older adults. Appl Physiol Nutr Metab 2016;41(8):863–71.
[108] Hansson ED, Srivatsan SR, Agrawal S, Menon KS, Delmonico MJ, Wang MQ, et al. Effects of strength training on physical function: influence of power, strength, and body composition. J Strength Cond Res 2009;23(9):2627–37.

[109] Zakrzewski W, Dobrzynski M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. Stem Cell Res Ther 2019;10(1):68.

[110] Bousout D, Barrera G, de la Maza P, Avendano M, Gattas V, Petermann M, et al. The impact of nutritional supplementation and resistance training on the health functioning of free-living Chilean elders: results of 18 months of follow-up. J Nutr 2001;131(9):2415–65.

[111] Dillon EL, Shef fl et al. Satellite-like cells contribute to pax7-dependent skeletal muscle repair in adult zebra fl et al. Muscle satellite cell heterogeneity and self-renewal. Front Cell Dev Biol 2014;2:41.

[112] Deutz NE, Pereira SL, Hays NP, Oliver JS, Edens NK, Evans CM, et al. Effect of beta-hydroxy-beta-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults. Clin Nutr 2013;32(5):704–12.

[113] Bukout D, Barrera G, de la Maza P, Avendano M, Gattas V, Petermann M, et al. The functioning of free-living Chilean elders: results of 18 months of follow-up. J Nutr 2001;131(9):2415–65.

[114] Dupont J, Dedeyne L, Dalle S, Kopp K, Gielen E. The role of omega-3 in the prevention and treatment of sarcopenia. Aging Clin Exp Res 2019;31(s):825–36.

[115] Hardee JP, Lynch GS. Current pharmacotherapies for sarcopenia. Expert Opin Pharmacother 2019;20(13):1645–57.

[116] Liguori I, Ruggo R, Aran I, Bulli G, Cerci F, Della-Morte D, et al. Sarcopenia: assessment of disease burden and strategies to improve outcomes. Clin Interv Aging 2018;13:913–27.

[117] Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GA, Schambelan M, et al. Liguori I, Ruggo R, Aran I, Bulli G, Cerci F, Della-Morte D, et al. Sarcopenia: assessment of disease burden and strategies to improve outcomes. Clin Interv Aging 2018;13:913–27.

[118] Munoz MF, Arguelles S, Medina R, Cano M, Ayala A. Adipose-derived stem cells decreased microglia activation and protected dopaminergic loss in rat lipopolysaccharide model. J Cell Physiol 2019;234(8):13762–72.

[119] Vukovich MD, Stubbs NB, Bohlken RM. Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults. J Nutr 2001;131(7):2049–52.

[120] Nagamara-Inoue T, Hara H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cell 2014;6(2):195–202.

[121] Vahidinia Z, Azami Tameh A, Nejati M, Beyer C, Talaei SA, Etehadi Moghadam S, et al. The protective effect of bone marrow mesenchymal stem cells in a rat model of ischemic stroke via reducing the C-Jun N-terminal kinase expression. Pathol Res Pract 2019;215(9):152519.

[122] Dalbrowoska S, Andrzejewska A, Lukomska B, Janowski M. Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles. J Neuroinflammation 2019;16(1):178.

[123] Chakar–Khiavi F, Dolati S, Chakar–Khiavi A, Abbaszadeh H, Aghebat-Maleki L, Pourlak T, et al. Prospects for the application of mesenchymal stem cells in Alzheimer’s disease treatment. Life Sci 2019;231:11656–64.

[124] Reza-Zaldivar EE, Hernandez-Sapiens MA, Gutierrez-Mercado YK, Sanzaval-Avila S, Gomez-Pinedo U, Marquez-Aguirre AL, et al. Mesenchymal stem cell-derived exosomes promote neurogenesis and cognitive function recovery in a mouse model of Alzheimer’s disease. Neural Regen Res 2019;14(9):1626–34.

[125] Vahidinia Z, Azami Tameh A, Nejati M, Beyer C, Talaei SA, Etehadi Moghadam S, et al. The protective effect of bone marrow mesenchymal stem cells in a rat model of ischemic stroke via reducing the C-Jun N-terminal kinase expression. Pathol Res Pract 2019;215(9):152519.

[126] Dabrowska S, Andrzejewska A, Lukomska B, Janowski M. Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles. J Neuroinflammation 2019;16(1):178.

[127] Vahidinia Z, Azami Tameh A, Nejati M, Beyer C, Talaei SA, Etehadi Moghadam S, et al. The protective effect of bone marrow mesenchymal stem cells in a rat model of ischemic stroke via reducing the C-Jun N-terminal kinase expression. Pathol Res Pract 2019;215(9):152519.

[128] Dabrowska S, Andrzejewska A, Lukomska B, Janowski M. Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles. J Neuroinflammation 2019;16(1):178.

[129] Chakar–Khiavi F, Dolati S, Chakar–Khiavi A, Abbaszadeh H, Aghebat-Maleki L, Pourlak T, et al. Prospects for the application of mesenchymal stem cells in Alzheimer’s disease treatment. Life Sci 2019;231:11656–64.